02:37 PM EDT, 10/28/2024 (MT Newswires) -- Eli Lilly ( LLY ) has received approval from Hong Kong authorities to launch its weight-loss prescription drug tirzepatide, branded as Mounjaro, in the territory, Bloomberg reported Sunday.

The sale of Mounjaro in a device called Kwikpen has been approved by the Hong Kong government for both long-term weight management and type 2 diabetes, according to the report, citing a company statement.

While the company has already secured approval for the injections for weight loss and diabetes to be also made available in mainland China, the timing of the launch there remains unclear, the report said.

Eli Lilly ( LLY ) did not immediately reply to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 896.93, Change: +4.23, Percent Change: +0.47